Statement re New Appointment

RNS Number:2194N
Amarin Corporation Plc
04 February 2008



         AMARIN APPOINTS DR. WILLIAM MASON AS LEAD INDEPENDENT DIRECTOR


LONDON, United Kingdom, February 4, 2008 - Amarin Corporation plc (NASDAQ:
AMRND) today announced that its Board of Directors has established the position
of Lead Independent Director and has appointed current board member, Dr. William
Mason, to that role. In his capacity as Lead Independent Director, Dr. Mason
will have the authority to convene meetings of the independent directors, and
will preside over those meetings, will coordinate the activities of the
independent directors, and will act as a liaison between the independent
directors, the Board and the Chairman.


The establishment of a Lead Independent Director and Dr. Mason's appointment to
that position follows the recent announcement by Amarin that Thomas Lynch,
Amarin's Chairman, has assumed the additional role of Chief Executive Officer of
Amarin.


Mr. Lynch commented, "Dr. Mason's appointment as our Lead Independent Director
reflects our ongoing commitment to maintaining high standards of corporate
governance. Dr. Mason is a valued non-executive board member, and an experienced
advisor to the pharmaceutical and biotechnology industry. We look forward to his
continued contribution to our business."


Dr. Mason added, "I am pleased to accept the new role of Lead Independent
Director and look forward to working with both Amarin's talented resource of
independent directors, as well as with Thomas Lynch, our experienced Chairman
and CEO, at what is a very exciting time for the Company. This is a valuable
step in the evolution of our high standards of governance. Amarin's Board of
Directors is committed to the highest level of corporate governance in our quest
to achieve value for all of our shareholders."


Dr. Mason has served as a non-executive board member of Amarin since July 2002,
is Chairman of the Company's Audit Committee and a member of Amarin's
Nominations Committee. Dr. Mason received his B.Sc. from Case Western Reserve
University in the United States and his doctorate in physiology from Trinity
College, Cambridge, UK in 1977. For twenty years he led a program of
neuroscience-focused medical research in Cambridge.


Dr. Mason also played an active role as a member of the Advisory Council on
Science and Technology (ACOST) in the UK Cabinet Office of HM Government,
developing government policy to create a highly qualified scientific and
technical manpower base in the UK. He has founded successful high technology
biomedical companies and has extensive commercial transactional experience in
the healthcare and life sciences sector. He maintains strong links with the
healthcare investment community. Currently, Dr. Mason is Chairman of
OrthoMimetics Ltd., Camlab Ltd. and Team Consulting Ltd., and is a director of
Sage Healthcare Ltd., Zygem Ltd. and Sphere Medical Ltd. He is also a member of
the 3i Independent Director's Program.


About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system (CNS) and cardiovascular diseases. Our goal is to be a leader in
the research, development and commercialization of novel drugs that address
unmet patient needs.


Amarin's CNS development pipeline includes the recently acquired myasthenia
gravis clinical program and preclinical programs in neuromuscular, neuronal
degenerative and inflammatory diseases; Miraxion for Huntington's disease; two
programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is
initiating a series of cardiovascular preclinical and clinical programs to
capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin also has two proprietary technology platforms, a
lipid-based technology platform for the targeted transport of molecules through
the liver and/or to the brain, and a unique mRNA technology based on cholinergic
neuromodulation.


Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively. In accordance with customary Nasdaq practice,
following Amarin's reverse stock split, which took effect from January 18, 2008,
a "D" will be appended to Amarin's Nasdaq ticker symbol for a period of 20
trading days and during that period Amarin's Nasdaq ticker symbol will appear as
"AMRND".



Contacts:

Amarin +353 (0) 1 669 9020

Thomas Lynch, Chairman and Chief Executive Officer

Alan Cooke, President and Chief Operating Officer

Darren Cunningham, EVP Strategic Development and Investor Relations

investor.relations@amarincorp.com


Investors:

Lippert/Heilshorn & Associates, Inc.

Anne Marie Fields +1 212 838 3777

Bruce Voss +1 310 691 7100


Media:

Powerscourt +44 (0) 207 250 1446

Rory Godson

Paul Durman

Sarah Daly

                                     # # #



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRBDGDDUDGGGIS
Amarin (LSE:AMRN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024